Friday, November 15, 2019
Ballroom: Salon H
1201 Market St.
This event is not part of the official Scientific Sessions 2019
as planned by the AHA Committee on Scientific
Registration for this program is now closed.
♦ Robert Giugliano, MD,SM (Chair)
♦ Robert Eckel, MD
♦ Pamela Morris, MD
♦ Peter Toth, MD, PhD
Despite the use of guideline-directed statin therapy, residual risk remains in individuals who have experienced a cardiovascular event. Moreover, recurrent cardiovascular events often occur within the first year after the initial event. Therefore, timely reduction of LDL-C with nonstatin therapies in patients at heightened risk is prudent for preventing major adverse cardiovascular outcomes. In this program, Chair Dr. Robert Giugliano will provide updates on LDL-C-lowering nonstatin therapy from the European Society of Cardiology meeting, as well as from recent publications. Then, faculty members Dr. Pamela Morris, Dr. Peter Toth, and Dr. Robert Eckel will identify, in an interactive case-presentation format, high risk patients for potential introduction of ezetimibe and PCSK9 inhibitors.
Accreditation & Credit Designation:
This educational activity is intended for cardiovascular